Han Zhu
-
- Chemotherapy-induced cardiotoxicity and mitigation 4
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 8
- CAR-T cell therapy research 7
- Peptidase Inhibition and Analysis 4
- HER2/EGFR in Cancer Research 3
- Neurology top 10%
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research 5
-
- Immune Cell Function and Interaction 4
-
- Lung Cancer Treatments and Mutations 3
- Co-authors
- Ronald WittelesSean M. WuSarah WalianyPatricia K. NguyenJoel W. NealMark M. DavisFederico DamilanoAnthony Rosenzweig
- Partner nations
- United StatesChinaIndia
In The Last Decade
Han Zhu
41 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 116
- Cardiology and Cardiovascular Medicine 415
- Oncology 344
- Cancer Research 146
- Neurology 138
- Infectious Diseases 162
Countries citing papers authored by Han Zhu
This map shows the geographic impact of Han Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Zhu more than expected).
Fields of papers citing papers by Han Zhu
This network shows the impact of papers produced by Han Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Zhu. The network helps show where Han Zhu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Han Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 3 | |
| 3 | 2025 | 9 | |
| 4 | 2025 | 2 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 25 | |
| 7 | 2023 | 9 | |
| 8 | 2023 | 14 | |
| 9 | 2022 | 103 | |
| 10 | 2022 | 13 | |
| 11 | 2022 | 7 | |
| 12 | 2022 | 12 | |
| 13 | 2021 | 6 | |
| 14 | 2021 | 77 | |
| 15 | 2021 | 4 | |
| 16 | 2020 | 49 | |
| 17 | 2020 | 5 | |
| 18 | 2017 | 9 | |
| 19 | 2015 | 63 | |
| 20 | 2007 | 96 |
About Han Zhu
Han Zhu is a scholar working on Oncology, Infectious Diseases and Hematology, having authored 44 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), CAR-T cell therapy research (7 papers), SARS-CoV-2 and COVID-19 Research (5 papers), Peptidase Inhibition and Analysis (4 papers), Immune Cell Function and Interaction (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), HER2/EGFR in Cancer Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (415 citations), Oncology (344 citations) and Cancer Research (146 citations). Han Zhu has collaborated with scholars based in United States, China and India. Frequent co-authors include Ronald Witteles, Sean M. Wu, Sarah Waliany, Patricia K. Nguyen, Joel W. Neal, Mark M. Davis, Federico Damilano, Anthony Rosenzweig, Colin Platt and Chunyang Xiao. Their work appears in journals such as JACC CardioOncology, Circulation Research, BioScience Trends, Current Cardiology Reports and Cell Metabolism.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.